Information only. We do not sell products or give medical advice. Consult a licensed physician / healthcare professional.

How to get the COA

Three action-first guides covering every step between placing a query and holding a verified Certificate of Analysis: how to request it, how to read batch and lot numbers, and what to ask before you ever place an order.

All guides

Reference guide

What Is a COA Build? How to Read One Correctly

A COA build is the full set of test parameters a lab reports together — identity, purity, and quantity — not any single number read in isolation. How the sections fit together, and the one check that confirms a certificate actually matches the material it claims to describe.

Regulatory guide

Is Semaglutide Legal in Ireland — What the HPRA Actually Authorises

Injectable Wegovy is HPRA-authorised as a prescription-only medicine under the Medicinal Products Regulations. Unlicensed powders, drops and nasal sprays sold online carry no HPRA authorisation and fall outside the legal supply chain.

How-to guide

How to Request a COA from a Supplier

The exact words to use, how to phrase the request, what to do when a supplier stalls, and the scripts that get a batch-specific certificate instead of a generic PDF.

Reference guide

Batch and Lot Numbers Explained

What batch and lot numbers actually mean, how manufacturers assign them, and the one cross-check that confirms a COA truly belongs to the material in your hand.

Pre-order checklist

What to Ask Before You Order

The full list of questions to send a supplier before committing: test method, issuing lab, accreditation, purity threshold, and how to read their answers for red flags.

Regulatory guide

Is Semaglutide Legal in the UK — MHRA Authorisations Explained

Injectable Wegovy is MHRA-authorised as a prescription-only medicine. Oral Wegovy received marketing authorisation in June 2026 — the first in Europe. Unlicensed powders, drops and patches fall outside the Human Medicines Regulations 2012.

Regulatory guide

Is Retatrutide Approved in the UK or Ireland — Regulatory Status 2026

Retatrutide (LY3437943) holds no marketing authorisation in any country as of mid-2026. The MHRA has confirmed it cannot be legally prescribed in the UK. TRIUMPH Phase 3 data gates the submission timeline — earliest 2026–2027, NHS 2028 at the soonest.